SPONSORED CONTENT
Uncertainty has become a constant in the 340B landscape. Legal challenges, shifting manufacturer policies, and evolving oversight have made one thing clear: waiting for definitive answers before taking action is no longer a viable strategy.
For covered
Virginia Drug Affordability Panel Bill Heads Back to Spanberger After Legislature Rejects Amendments


Q: What is the primary problem 340B Referral Compass solves?
Referral Compass helps covered entities (CEs) address one of the most difficult and often underdeveloped areas…
Read More »









